Avrobio Inc Expected To Post A Loss Of 28 Cents A Share: Earnings Preview

Tectonic Therapeutic

03/11/2023 15:18

* AVROBIO Inc  AVRO.OQ   AVRO.O  is expected to show no
change in
quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for AVROBIO Inc is for
a loss
of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AVROBIO Inc
is
$4​, above​ its last closing price of $1.57. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.21       -0.07      -0.37     Missed  -395
 Mar. 31 2023  -0.54       -0.54      -0.57     Missed  -4.6
 Dec. 31 2022              -0.49      -0.57     Missed  -15.7​
 Sep. 30 2022  -0.57       -0.55      -0.52     Beat    5.5
 ​​Jun.        -0.59       -0.57      -0.64     Missed  -11.8
 30 2022                                                
 Mar. 31 2022  -0.58       -0.59      -0.68     Missed  -14.8​
 Dec. 31 2021  -0.71       -0.74      -0.65     Beat    12.2
 Sep. 30 2021  -0.75       -0.76      -0.75     Beat    1
 This summary was machine generated November 3 at 15:18 GMT.  All
figures in US dollars  unless otherwise stated